Cargando…

PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer

Introduction: Endocrine therapy has played an important role in the management of ER positive breast cancer over recent decades. Despite this, not all patients respond equally to endocrine intervention, which can lead to resistance, associated disease relapse and progression. Previous reports sugges...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rees, Michael, Smith, Chris, Barrett-Lee, Peter, Hiscox, Steve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771710/ https://www.ncbi.nlm.nih.gov/pubmed/33473257 http://dx.doi.org/10.18632/oncotarget.27846

Ejemplares similares

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2015)

SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance
por: Liu, Zexuan, et al.
Publicado: (2022)

An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment
por: Tang, Jianing, et al.
Publicado: (2019)

Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes
por: Daniel, Andrea R., et al.
Publicado: (2014)

Expression of estrogen receptors, PELP1, and SRC in human spermatozoa and their associations with semen quality
por: Skibińska, Izabela, et al.
Publicado: (2022)

microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
por: Howard, Erin W., et al.
Publicado: (2018)

PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer
por: Truong, Thu H., et al.
Publicado: (2021)

The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer
por: Rodriguez, David, et al.
Publicado: (2019)

Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer
por: Pizon, Monika, et al.
Publicado: (2018)

Expression of ERα, ERβ and Co-Regulator PELP1/MNAR in Colorectal Cancer: Prognostic Significance and Clinicopathologic Correlations
por: Grivas, Petros D., et al.
Publicado: (2009)

Estrogen receptor (ER) was regulated by RNPC1 stabilizing mRNA in ER positive breast cancer
por: Shi, Liang, et al.
Publicado: (2015)

Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy
por: Kawiak, Anna, et al.
Publicado: (2022)

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers
por: Nath, Aritro, et al.
Publicado: (2022)

ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance
por: Strillacci, Antonio, et al.
Publicado: (2022)

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022)

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
por: Laible, Mark, et al.
Publicado: (2019)

Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor–Positive Early Breast Cancer
por: Cheung, Yee-Ming, et al.
Publicado: (2019)

Corrigendum: Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
por: Ellis, Matthew J., et al.
Publicado: (2008)

Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers
por: Groenendijk, Floris H., et al.
Publicado: (2019)

Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005)

Review of bone health in women with estrogen receptor–positive breast cancer receiving endocrine therapy
por: Malagrinò, Matteo, et al.
Publicado: (2023)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

Regulation of rDNA Transcription by Proto-Oncogene PELP1
por: Gonugunta, Vijay K., et al.
Publicado: (2011)

Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models
por: Michmerhuizen, Anna R., et al.
Publicado: (2022)

Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR
por: Vadlamudi, Ratna K., et al.
Publicado: (2007)

The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer
por: Aust, Stefanie, et al.
Publicado: (2013)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
por: Batra, Atul, et al.
Publicado: (2020)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

ER-α36-Mediated Rapid Estrogen Signaling Positively Regulates ER-Positive Breast Cancer Stem/Progenitor Cells
por: Deng, Hao, et al.
Publicado: (2014)

Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer
por: Jia, Yan, et al.
Publicado: (2019)

ENDOCRINE DISRUPTORS: Estrogens in a Bottle?
por: Barrett, Julia R.
Publicado: (2009)

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
por: Xu, Jing, et al.
Publicado: (2023)

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
por: Sanchez, Cesar G, et al.
Publicado: (2011)

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?
por: Haricharan, Svasti, et al.
Publicado: (2017)

Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
por: Leung, Euphemia Y., et al.
Publicado: (2017)

Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study
por: Xie, Yuxin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dm6u9bpi6sh4mb7uq5hu6mlqig